EPA063	Enhanced functional cytotoxic cell populations in PBMCs from individuals with HIV on treatment with ART and dasatinib	E-poster	Immunotherapy (including broadly neutralizing antibodies)
EPA064	Broadly neutralizing HIV-1 antibodies as a PrEP modality among young sexual minority men: a conjoint experiment	E-poster	Immunotherapy (including broadly neutralizing antibodies)
OAA0405	Temsavir treatment of HIV-1-infected cells decreases envelope glycoproteins recognition by broadly-neutralizing antibodies	Oral abstract session with live Q&A	Immunotherapy (including broadly neutralizing antibodies)
PELBA02	First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV	Poster exhibition	Immunotherapy (including broadly neutralizing antibodies)
PEMOA26	Developing a novel HIV cure strategy: retargeting potent cytotoxic T cells to kill HIV-infected cells	Poster exhibition	Immunotherapy (including broadly neutralizing antibodies)
PEMOA27	Clinical and immunometabolic patterns determining efficacy of DC-treatment reinvigorating HIV-1-specific CD8+ T cells in PLWH	Poster exhibition	Immunotherapy (including broadly neutralizing antibodies)
PEMOA28	Pharmacologic intervention to reduce chronic inflammation in people with HIV	Poster exhibition	Immunotherapy (including broadly neutralizing antibodies)
EPB001	Factors influencing immune restoration in people living with HIV/AIDS	E-poster	Impact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression
EPB002	Reduced selection of unfavourable HLA-I in mother-to-child HIV transmission in KwaZulu Natal, South Africa	E-poster	Impact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression
EPE416	Revisiting sustainable financing for the HIV/AIDS response in the COVID-19 era	E-poster	Impact of COVID-19 on financing for the HIV response